# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global ...
JP Morgan analyst James Gordon maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $500 to $640.
Barclays analyst Charles Pitman upgrades argenx (NASDAQ:ARGX) from Equal-Weight to Overweight.
Baird analyst Joel Beatty maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $490 to $515.